NASDAQ: MENSJyong Biotech Ltd Stock
$2.01-0.07 (-3.37%)
Updated May 15, 2026
MENS Price
$2.01
Fair Value Price
-$0.24
Market Cap
$152.82M
52 Week Low
$1.43
52 Week High
$67.00
P/E
-33.5x
P/B
-6.14x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$4.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.83
Operating Cash Flow
-$3M
Beta
2.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MENS Overview
Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MENS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MENS
Ranked#125 of 462
Ranked#125 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $228.77 | A | |
| $50.13 | A | |
| $1.98 | A |
Be the first to know about important MENS news, forecast changes, insider trades & much more!
MENS News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MENS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MENS ($2.01) is overvalued by 947.23% relative to our estimate of its Fair Value price of -$0.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MENS ($2.01) is not significantly undervalued (947.23%) relative to our estimate of its Fair Value price of -$0.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MENS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MENS due diligence checks available for Premium users.
Valuation
MENS fair value
Fair Value of MENS stock based on Discounted Cash Flow (DCF)
Price
$2.01
Fair Value
-$0.24
Undervalued by
947.23%
MENS ($2.01) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MENS ($2.01) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MENS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MENS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-33.5x
Industry
16.9x
Market
22.67x
MENS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.14x
Industry
4.83x
MENS's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
MENS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$20.8M
Liabilities
$45.7M
Debt to equity
-1.83
MENS's short-term liabilities ($34.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MENS's short-term assets ($15.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MENS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MENS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
MENS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MENS vs Biotech Stocks
Jyong Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.